Hemab Therapeutics Holdings, Inc. Common Stock
COAGАкція
$32.37
Капіталізація$1.51B
P/E—
Див. дохідність—
Бета-0.26
Графік ціни
Улюблені метрики
Ціна відносно S&P 500 (4 тиж.)1.69%
Загальна оцінка (VGM)21.80
Ринкова капіталізація$1.51B
Рекомендації аналітиків
черв. 2026 р.
4.22
Порівняння з галуззю — Біологічні препарати(180)
| Символ | Оцінка недооціненості | Оцінка зростання | Оцінка моментуму | Ціна |
|---|---|---|---|---|
COAGHemab Therapeutics Holdings, Inc. Common Stock | — | — | D | $32.37 |
| AMGNAmgen Inc | C | C | C | $358.33 |
| GILDGilead Sciences Inc | C | B | C | $127.88 |
| ARGXargenx SE American Depositary Shares | D | A | B | $887.18 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $182.08 |
| BIIBBiogen Inc. Common Stock | C | D | B | $216.03 |
| MRNAModerna, Inc. Common Stock | D | B | A | $67.27 |
| BNTXBioNTech SE American Depositary Share | C | C | C | $91.22 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $168.52 |
| EXELExelixis Inc | C | B | B | $54.77 |
| TECHBio-Techne Corp. | D | C | B | $71.00 |
Про акцію
Hemab Therapeutics Holdings Inc is a clinical-stage biotechnology company developing therapies for the treatment of blood coagulation disorders. It focuses on discovering, developing, and commercializing treatments for conditions such as Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease. Its flagship candidate, sutacimig (HMB-001), is a bispecific antibody currently in clinical trials for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency. The company has one operating segment, engaged in the research and development of prophylactic therapeutics for bleeding disorders.